Literature DB >> 12797521

Intracellular expression of CD69 in endometrial and peripheral T cells represents a useful marker in women with recurrent miscarriage: modulation after allogeneic leukocyte immunotherapy.

R Ramhorst1, V García, E Agriello, A Corigliano, E Etchepareborda, M Irigoyen, Gómez Pasanante, L Fainboim.   

Abstract

PROBLEM: To characterize in fertile women and women with recurrent spontaneous abortions (RSA) the expression and functional status of T cells expressing the CD69 molecule. METHOD OF STUDY: We analyzed by flow cytometry in peripheral blood and endometrium from fertile and RSA women, the surface and cytoplasmic expression of CD69 on gated T cells. In addition, we investigated by three-color flow cytometry the expression of cytokines, and subsets of memory T cells.
RESULTS: In T cells, CD69 was restricted to the intracellular compartment with a higher frequency in RSA than in fertile women (68.2 +/- 12% versus 23.7 +/- 22%, P < 0.001, and 20 +/- 9.5% versus 2.1 +/- 3.8%, P < 0.005, in endometrium and peripheral blood, respectively). In contrast, the number of interferon-gamma+ (IFN-gamma+) secreting cells was higher (16 +/- 5% versus 6 +/- 1%) in fertile women. All 11 RSA women alloimmunized with parental leukocytes reached values of CD3 +/- CD69+ cells similar to those observed in fertile women.
CONCLUSIONS: CD69 might represent a useful marker in the diagnosis and the follow up of RSA patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797521     DOI: 10.1034/j.1600-0897.2003.00021.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  2 in total

1.  Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers.

Authors:  W Jennes; D Evertse; M-Y Borget; B Vuylsteke; C Maurice; J N Nkengasong; L Kestens
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

Review 2.  Memory T Cells in Pregnancy.

Authors:  Tom E C Kieffer; Anne Laskewitz; Sicco A Scherjon; Marijke M Faas; Jelmer R Prins
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.